Stockholders to Vote on Massive Dilution, Reverse Split to Avert Insolvency and Delisting

summarizeSummary

Gossamer Bio is seeking stockholder approval for a distressed debt exchange involving massive share dilution, a significant increase in authorized shares, and a reverse stock split, all critical measures to avoid insolvency and Nasdaq delisting.

check_boxKey Events · Financing and Capital Events · GOSS

• Distressed Debt Exchange

  The company is proposing an exchange offer for its outstanding $200 million convertible notes, replacing them with up to $72 million in new 7.50% Convertible Senior Secured First Lien Notes due 2030 and up to 317,647,058 shares of common stock.

• Massive Share Dilution

  The initial exchange will result in approximately 135% dilution for existing shareholders. If all new convertible notes fully convert, existing shareholders face potential dilution of up to 370% from the original outstanding shares.

• Authorized Share Increase

  Stockholders will vote to increase the authorized common stock from 700,000,000 to 4,000,000,000 shares to support the new issuances from the debt exchange and future equity incentive grants.

• Reverse Stock Split Proposal

  The Board seeks authority to effect a reverse stock split at a ratio between 1-for-10 and 1-for-150 to regain compliance with Nasdaq's minimum $1.00 bid price requirement, following a delisting notice received on April 8, 2026.

auto_awesomeAnalysis · GOSS · Life Sciences

This preliminary proxy statement details critical proposals for a special stockholder meeting, outlining the company's plan to address severe financial distress, a going concern warning, and a Nasdaq delisting notice. The core of the plan is a distressed debt exchange that will result in immediate and substantial dilution for existing shareholders, with potential for further dilution upon conversion of new notes. To facilitate this, the company needs to significantly increase its authorized share count. Additionally, a reverse stock split is proposed to regain Nasdaq compliance. Failure to approve these measures could lead to insolvency or bankruptcy, making these votes crucial for the company's continued operation.